We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gilead Sciences, Inc. today announced findings from a pulse survey conducted to evaluate the impact of the COVID-19 pandemic on the access and delivery of care in HIV, which includes testing, treatment and prevention, in Asia Pacific.